The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health ...

Results from the study, which focused on gynecological malignant tumors, were presented at the Society for Immunotherapy of ...

Its top-selling treatment, Keytruda, will lose patent protection in a few years. Then Merck will face biosimilar competition ...

Investors should monitor R&D updates closely, as Merck's future hinges on new drug developments amid looming patent expirations. Keytruda is now under threat not only from patent expiries but also ...

Merck's consistent dividend payments over 34 years, healthy balance sheet, and attractive valuation highlight its investment ...

The results will help Keytruda take a further bite out of its ... factor that benefits Merck against BMS as Inlyta will lose its patent protection in 2025 “It would appear that Merck has managed ...

Keytruda, a cancer treatment drug, has achieved $25 billion in global sales. Its mechanism boosts the immune system to fight cancer. In India, its high cost limits access. With patents expiring soon, ...

However, Merck will then lose patent exclusivity for its cash cow, so Keytruda's sales will drop off a cliff, likely dragging Merck's entire revenue along with it. Thankfully, Merck has a plan.

Furthermore, Keytruda will lose patent exclusivity in the U.S. in 2028 and then face generic competition. That said, Keytruda's revenue should continue growing until 2028 even if ivonescimab hits ...

Keytruda (pembrolizumab) is a prescription drug that’s used to treat certain forms of cancer. Keytruda comes as an intravenous (IV) infusion (an injection into your vein given over time ...

Despite the upcoming headwind that will be generated by Keytruda's loss of patent protection, the odds are good that Merck will be able to provide decent returns to its shareholders up to the ...